Oral treatment with trimethoprim-sulfamethoxazole and zidovudine suppresses murine accessory cell-dependent immune responses

Toxicological Sciences

Volumn 55, Issue 2, 2000, Pages 335-342

  Freund, Yvonne R ^a   Dousman, Linda ^a   MacGregor, James T ^a,b   Mohagheghpour, Nahid ^a  

^a SRI INTERNATIONAL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Accessory cells; Immunosuppression; Pneumocystis carinii pneumonia; Trimethoprim sulfamethoxazole; Zidovudine

Indexed keywords

CONCANAVALIN A; COTRIMOXAZOLE; LIPOPOLYSACCHARIDE; ZIDOVUDINE;

ACCESSORY CELL; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HEMATOPOIESIS; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MACROCYTIC ANEMIA; MACROPHAGE; MOUSE; NONHUMAN; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

ANIMALIA; MURINAE; PNEUMOCYSTIS CARINII;

EID: 0034084396     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/55.2.335     Document Type: Article

References (58)

1. Allegra, C. J., Kovacs, J. A., Drake, J. C., Swan, J. C., Chabner, B. A., and Masur, H. (1987). Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J. Exp. Med. 165, 926-931.
2. Anderson, R., Grabow, G., Oosthuizen, R., Theron, A., and van Rensburg, A. J. (1980). Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effect of co-trimoxazole. Antimicrob. Agents Chemother. 17, 322-326.
3. Arya, S. (1998). Antiretroviral therapy in countries with low health expenditure. Lancet 351, 1433-1434.
4. Buhl, R., Jaffe, H. A., Holroyd, K. J., Wells, F. B., Mastrangeli, A., Saltini, C., Cantin, A. M., and Crystal, R. G. (1989). Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 2, 1294-1298.
5. Cameron, D. W., Heath-Chiozzi, M., Danner, S., Cohen, C., Kravcik, S., Maurath, C., Sun, E., Henry, D., Rode, R., Potthoff, A., and Leonard, J. (1998). Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351, 543-549.
6. Canas, E., Pachon, J., Garcia-Pesquera, F., Castillo, J. R., Viciana, P., Cisneros, J. M., and Jimenez-Mejias, M. E. (1996). Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 40, 230-233.
7. Carr, A., Tindall, B., Penny, R., and Cooper, D. A. (1993). In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin. Exp. Immunol. 94, 21-25.
8. Centers for Disease Control (CDC). (1989). Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. JAMA 262, 335-339.
9. Centers for Disease Control (CDC). (1992). Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb. Mortal. Wkly. Rep. 41, 1-11.
10. Chappel, W. R., and Mordenti, J. (1991). Extrapolation of toxicological and pharmacological data from animals to humans. In Advances in Drug Research (B. Testa, Ed.), pp. 2-112. Academic Press, New York.
11. Climax, J., Lenehan, T. J., Lambe, R., Kenny, M., Caffrey, E., and Darragh, A. (1986). Interaction of antimicrobial agents with human peripheral blood leucocytes: Uptake and intracellular localization of certain sulphonamides and trimethoprims. J. Antimicrob. Chemother. 17, 489-498.
12. Cribb, A. E., Lee, B. L., Trepanier, L. A., and Speilberg, S. P. (1996). Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15, 9-50.
13. Cribb, A. E., Miller, M., Leeder, J. S., Hill, J., and Spielberg, S. P. (1991). Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Drug Metab. Dispos. 19, 900-906.
14. Cribb, A. E., Miller, M., Tesoro, A., and Spielberg, S. P. (1990). Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol. Pharmacol. 38, 744-751.
15. Cribb, A. E., Spielberg, S. P., and Griffin, G. P. (1995). N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23, 406-414.
16. Cronkite, E. P., and Bullis, J. (1990). In vivo toxicity of 3′-azido-3′-deoxythymidine (AZT) on CBA/Ca mice. Int. J. Cell Cloning 8, 332-345.
17. Daftarian, M. P., Filion, L. G., Cameron, W., Conway, B., Roy, R., Tropper, F., and Diaz-Mitoma, F. (1995). Immune response to sulfamethoxazole in patients with AIDS. Clin. Diagn. Lab. Immunol. 2, 199-204.
18. Farrar, J. J., Fuller-Farrar, J., Simon, P. L., Hilfiker, M. L., Stadler, B. M., and Farrar, W. L. (1980). Thymoma production of T cell growth factor (Interleukin 2). J. Immunol. 125, 2555-2558.
19. Forsgren, A., Back, G., Beckman, H., and Bellahsene, A. (1980). Antibiotic-host defense interactions in vitro and in vivo. Scand. J. Infect. Dis. Suppl. 24, 195-203.
20. Freund, Y. R., Riccio, E. S., Phillips, S. J., Dousman, L., and MacGregor, J. T. (1998). Pyrimethamine impairs host resistance to infection with Listeria monocytogenes in BALB/c mice. Toxicol. Sci. 42, 91-98.
21. Gill, H. J., Hough, S. J., Naisbitt, D. J., Maggs, J. L., Kitteringham, N. R., Pirmohamed, M., and Park, B. K. (1997). The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. 282, 759-801.
22. Gordin, F. M., Simon, G. L., Wofsy, C. B., and Mills, J. (1984). Adverse reactions to trimethoprim-sulfomethoxazole in patients with acquired immunodeficiency syndrome. Ann. Intern. Med. 100, 495-499.
23. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Jr., Feinberg, J. E., Balfour, H. H. Jr., Deyton, L. R., Chodakewitz, J. A., and Fischl, M. A. (1999). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. The AIDS Clinical Trial Group 320 Study Team. N. Engl. J. Med. 337, 725-733.
24. Hardy, W. D., Feinberg, J., Finkelstein, D. M., Power, M. E., He, W., Kaczka, C., Frame, P. T., Holmes, M., Waskin, H., Fass, R. J., Powderly, W. G., Steigbigel, R. T., Zugar, A., and Holzman, R. S. (1992). A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophlaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N. Engl. J. Med. 327, 1842-1848.
25. Hess, D. A., Bird, I. A., Almawi, W. Y., and Rieder, M. J. (1997). The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation. J. Pharmacol. Exp. Ther. 281, 540-548.
26. Hughes, W. T., Rivera, G. K., Schell, M. J., Thornton, D., and Lott, L. (1987). Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N. Engl. J. Med. 316, 1627-1632.
27. Kovacs, J. A., Allegra, C. J., Beaver, J., Boarman, D., Lewis, M., Parrillo, J. E., Chabner, B., and Masur, H. (1989). Characterization of de novo folate synthesis of Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J. Infect. Dis. 160, 312-320.
28. Kovacs, J. A., Hiemenz, J. W., Macher, A. M., Stover, D., Murray, H. W., Shelhamer, J., Lane, H. C., Urmacher, C., Honic, C., Longo, D. L., Parker, M. M., Natanson, C., Parrillo, J., Fauci, A. S., Pizzo, P. A., and Masur, H. (1984). Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency virus. Ann. Intern. Med. 100, 663-671.
29. Larsson, E. L., Iscove, N. N., and Coutinho, A. (1980). Two distinct factors are required for induction of T-cell growth. Nature 283, 664-666.
30. Leeder, J. S., Nakhooda, A., Spielberg, S. P., and Dosch, H. M. (1991). Cellular toxicity of sulfamethoxazole reactive metabolites: II. Inhibition of natural killer activity in human peripheral blood mononuclear cells. Biochem. Pharmacol. 41, 575-583.
31. Luster, M. I., Germolec, D. R., White, K. L., Jr., Fuchs, B. A., Fort, M. M., Tomaszewski, J. E., Thompson, M., Blair, P. C., McCay, J. A., Munson, A. E., and Rosenthal, G. J. (1989). A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment. Toxicol. Appl. Pharmacol. 101, 328-339.
32. Luster, M. I., Munson, A. E., Thomas, P. T., Holsapple, M. P., Fenters, J. D., White, K. L., Jr., Lauer, L. D., Germolec, D. R., Rosenthal, G. J., and Dean, J. H. (1988). Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fundam. Appl. Toxicol. 10, 2-19.
33. Malek, T. R., Schmidt, J. A., and Shevach, F. M. (1985). The murine IL2 receptor: III. Cellular requirements for the induction of IL2 receptor expression on T cell subpopulations. J. Immunol. 134, 2405-2413.
34. Masur, H., Lane, H. C., Kovacs, J. A., Allegra, C. J., and Edman, J. C. (1989). NIH Conference. Pneumocystis pneumonia: from bench to clinic. Ann. Intern. Med. 111, 813-826.
35. Medina, I., Mills, J., Leoung, G., Hopewell, P. C., Lee, B., Modin, G., Benowitz, N., and Wofsy, C. B. (1990). Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N. Engl. J. Med. 323, 776-782.
36. Michelet, C., Arvieux, C., Francois, C., Besnier, J. M., Rogez, J. P., Breux, J. P., Souala, F., Allavena, C., Raffi, F., Garre, M., and Cartier, F. (1998). Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 12, 1815-1822.
37. Naisbitt, D. J., Hough, S. J., Gill, H. J., Pirmohamed, M.. Kitteringham, N. R., and Park, B. K. (1999). Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. 126, 1393-1407.
38. Nakajima, H., Sano, H., Nihimura, T., Yoshida, S., and Iwamoto, I. (1994). Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T-cell recruitment into the tissue. J. Exp. Med. 179, 1145-1154.
39. Pacifici, R., Bacosi, A., Caronna, A., Di Carlo, S., Pichini, S., and Zuccaro, P. (1992). Immunological consequences of zidovudine treatment in control and morphine or methadone treated mice. Immunopharmacol. Immunotoxicol. 14, 355-381.
40. Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., Jackson, G. G., Durack, D. T., and Nusinoff-Lehrman, S. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trail. The AZT Collaborative Working Group. N. Engl. J. Med. 317, 192-197.
41. Rieder, M. J., Krause, R., and Bird, I. A. (1995). Time-course of toxicity of reactive sulfonamide metabolites. Toxicology 95, 141-146.
42. Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K., and Spielberg, S. P. (1991). Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmacol. Ther. 49, 13-17.
43. Rieder, M. J., Sisson, E., Bird, I. A., and Almawi, W. Y. (1992). Suppression of T-lymphocyte proliferation by sulphonamide hydroxylamines. Int. J. Immunopharmacol. 14, 1175-1180.
44. Rieder, M. J., Uetrecht, J., Shear, N. H., Cannon, M., Miller, M., and Spielberg, S. P. (1989). Diagnosis of sulphonamide hypersensitivity reactions by in vitro "rechallenge" with hydroxylamine metabolites. Ann. Intern. Med. 110, 286-289.
45. Safrin, S., Finkelstein, D. M., Feinberg, J., Frame, P., Simpson, G., Wu, A., Cheung, T., Soeiro, R., Hojczyk, P., and Black, J. R. (1996). Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann. Intern. Med. 124, 792-802.
46. Sattler, F. R., Cowan, R., Nielsen, D. M., and Ruskin, J. (1988). Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective, noncrossover study. Ann. Intern. Med. 109, 280-287.
47. Schneider, M. M., Hoepelman, A. L., Eeftinck Schattenkerk, J. K., Nielsen, T. L., van Der Graaf, Y., Frissen, J. P., van Der Ende, I. M., Kolsters, A. F., and Borleffs, J. C. (1992). A controlled trail of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N. Engl. J. Med. 327, 1836-1841.
48. Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F., and Pichler, W. J. (1997). Direct, MHC-dependent presentation of the drug sulfamethoxazole to human ab T-cell clones. J. Clin. Invest. 100, 136-141.
49. Shear, N. H., Spielberg, S. P., Grant, D. M., Tang, B. K., and Kalow, W. (1986). Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann. Intern. Med. 105, 179-184.
50. Smith, K. A., Lachman, L. B., Oppenheim, J. J., and Favata, M. F. (1980). The functional relationship of the interleukins. J. Exp. Med. 151, 1551-1556.
51. Stephenson, J. (1998). Studies reveal early impact of HIV infection, effects of treatment. JAMA 279, 641-642.
52. Stephenson, J. (1999). AIDS researchers target poor adherence. JAMA 281, 1069.
53. van der Ven, A. J., Koopmans, P. P., Vree, T. B., and van der Meer, J. W. (1991). Adverse reactions to co-trimoxazole in HIV infection. Lancet 338, 431-433.
54. Viora, M., De Luca, A., D'Ambrosio, A., Antinori, A., and Ortona, E. (1996). In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob. Agents Chemother. 40, 1294-1297.
55. von Greyerz, S., Zanni, M. P., Frutig, K., Schnyder, B., Burkhart, C., and Pichler, W. J. (1999). Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human αβ+ T cell clones. J. Immunol. 162, 592-602.
56. Vree, T. B., vein der Ven, A. J., Koopmans, P. P., van Ewijk-Beneken Kolmer, E. W., and Verwey-van Wissen, C. P. (1995). Pharmacokinetics of sulphamethoxazole with its hydroxy metabolites and N4-acetyl N1-glucuronide conjugate in healthy human volunteers. Clin. Drug Invest. 9, 43-53.
57. Wharton, J. M., Coleman, D. L., Wofsy, C. B., Luce, J. M., Blumenfeld, W., Hadley, W. K., Ingram-Drake, L., Volberding, P. A., and Hopewell, P. C. (1986). Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective randomized trail. Ann. Intern. Med. 105, 37-44.
58. Winston, D. J., Lau, W. K., Gale, R. P., and Young, L. S. (1980). Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann. Intern. Med. 92, 762-769.